Lipid metabolic networks, Mediterranean diet and cardiovascular disease in the PREDIMED trial.

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA. Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain. IDISNA (Instituto de Investigación Sanitaria de Navarra), Pamplona, Spain. CIBER Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III, Madrid, Spain. Human Nutrition Unit, Faculty of Medicine and Health Sciences, Institut d'Investigació Sanitària Pere Virgili, Rovira i Virgili University, Reus, Spain. Department of Preventive Medicine, University of Valencia, Valencia, Spain. Department of Preventive Medicine, University of Málaga, Málaga, Spain. Institute of Health Sciences IUNICS, University of Balearic Islands and Hospital Son Espases, Palma de Mallorca, Spain. Department of Internal Medicine, Institut d'Investigacions Biomediques August Pi Sunyer (IDI- BAPS), University of Barcelona, Barcelona, Spain. Lipid Clinic, Department of Endocrinology and Nutrition, Institut d'Investigacions Biomediques August Pi Sunyer (IDI- BAPS), University of Barcelona, Barcelona, Spain. Department of Family Medicine, Primary Care Division of Sevilla, San Pablo Health Center, Sevilla, Spain. Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, Barcelona, Spain. Department of Cardiology, University Hospital of Alava, Vitoria, Spain. Department of Clinical Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain. Broad Institute and MIT, Harvard University, Cambridge, MA, USA. Department of Epidemiology. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. Channing Division for Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, MA, USA.

International journal of epidemiology. 2018;(6):1830-1845

Other resources

Abstract

BACKGROUND Perturbed lipid metabolic pathways may play important roles in the development of cardiovascular disease (CVD). However, existing epidemiological studies have focused more on discovering individual lipid metabolites for CVD risk prediction rather than assessing metabolic pathways. METHODS This study included a subcohort of 787 participants and all 230 incident CVD cases from the PREDIMED trial. Applying a network-based analytical method, we identified lipid subnetworks and clusters from a global network of 200 lipid metabolites and linked these subnetworks/clusters to CVD risk. RESULTS Lipid metabolites with more double bonds clustered within one subnetwork, whereas lipid metabolites with fewer double bonds clustered within other subnetworks. We identified 10 lipid clusters that were divergently associated with CVD risk. The hazard ratios [HRs, 95% confidence interval (CI)] of CVD per a 1-standard deviation (SD) increment in cluster score were 1.39 (1.17-1.66) for the hydroxylated phosphatidylcholine (HPC) cluster and 1.24 (1.11-1.37) for a cluster that included diglycerides and a monoglyceride with stearic acyl chain. Every 1-SD increase in the score of cluster that included highly unsaturated phospholipids and cholesterol esters was associated with an HR for CVD of 0.81 (95% CI, 0.67-0.98). Despite a suggestion that MedDiet modified the association between a subnetwork that included most lipids with a high degree of unsaturation and CVD, changes in lipid subnetworks/clusters during the first-year follow-up were not significantly different between intervention groups. CONCLUSIONS The degree of unsaturation was a major determinant of the architecture of lipid metabolic network. Lipid clusters that strongly predicted CVD risk, such as the HPC cluster, warrant further functional investigations.

Methodological quality

Metadata

MeSH terms : Lipids